DAXOR CORP. 10-Q Summary: Quarter Ended September 30, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, and the nine-month period ended on the same date. Daxor Corporation is a medical device manufacturer focused on the Blood Volume Analyzer (BVA-100) and cryobanking services (Scientific Medical Systems Corp.). The company maintains a significant investment portfolio, primarily in utility stocks, to fund operations and offset operating losses. The filing includes restated comparative figures for 2005 due to prior accounting adjustments.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 |
|---|---|---|
| Total Revenues | $420,140 | $1,151,608 |
| Net Income (Loss) | $(927,792) | $(832,454) |
| Operating Loss | $(1,243,384) | $(4,041,109) |
| Investment Income (Net) | $402,888 | $3,476,411 |
| Cash and Equivalents | $102,073 | $102,073 (Ending Balance) |
| Available-for-Sale Securities | $62,275,112 | $62,275,112 (Ending Balance) |
| Total Assets | $67,111,732 | $67,111,732 (Ending Balance) |
| Total Liabilities | $25,108,312 | $25,108,312 (Ending Balance) |
| Stockholders' Equity | $42,003,420 | $42,003,420 (Ending Balance) |
Note: The company reported a net loss for both periods, significantly offset by investment income. Operating cash flow for the nine months ended Sep 30, 2006, was $748,842.
Material Changes vs. Prior Period
- Revenue Decline (Q3): Operating revenues decreased 6.1% to $420,140 in Q3 2006 compared to $447,652 in Q3 2005. This was primarily due to a one-time royalty receipt of $97,729 in 2005 from the sale of cryobanking technology.
- Revenue Growth (9 Months): Operating revenues increased 11.2% to $1,151,608 for the nine months ended Sep 30, 2006, driven by a 34.8% increase in blood volume kit sales following the correction of a Medicare reimbursement error for the Volumex kit.
- Cryobanking Segment: Revenues from cryobanking services dropped significantly (56.3% in Q3, 30.0% in 9 months) compared to 2005, largely attributable to the absence of the one-time 2005 royalty income.
- Investment Performance: Net investment income decreased in Q3 2006 ($402,888) compared to Q3 2005 ($2,209,396), largely due to a one-time non-cash dividend recorded in 2005 and a mark-to-market loss on short positions of $734,010 in Q3 2006 versus a gain in 2005.
- Operating Expenses: Total operating expenses increased 6.0% in Q3 and 13.1% for the nine months, driven by expanded R&D and marketing efforts for the BVA-100.
Outlook, Risks, and Management Commentary
- Medicare Reimbursement: Management notes that the correction of the Medicare reimbursement error for the Volumex kit in early 2006 has renewed interest in the BVA-100, leading to 14 signed trial agreements in the first nine months of 2006 (compared to 14 for all of 2005).
- R&D Focus: The company is continuing R&D on Glomerular Filtration Rate (GFR), Total Body Albumin Analysis, and a needle-free delivery device (Max-200).
- Liquidity Strategy: The investment portfolio remains critical to funding operations. The portfolio has maintained a value above historical cost for 87 consecutive quarters. Management states current resources are adequate for current R&D and marketing levels but may not support a nationwide marketing expansion without additional capital.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting as of June 30, 2006, due to insufficient personnel with GAAP expertise. This led to restatements of prior years. Management has hired a CPA to oversee accounting and is implementing remediation.
- Investment Company Status: The filing includes a detailed response to the SEC regarding whether Daxor qualifies as an "Investment Company." Management asserts it is a bona fide R&D company relying on the "ICOS Order" safe harbor, as investment income is used to fund operations and R&D expenses are substantial.
Key Facts for Investor Verification
- Restatements: Verify the impact of the restated 2005 figures and the specific accounting adjustments made in the amended 10-K/A filed in November 2006.
- Investment Portfolio Risk: Assess the concentration risk in utility stocks and the volatility of "mark-to-market" adjustments on short positions and options, which significantly impact net income.
- Internal Control Remediation: Monitor the effectiveness of the new internal controls and the hiring of accounting personnel to prevent future restatements.
- Medicare Dependency: Evaluate the sustainability of revenue growth given the reliance on Medicare reimbursement rates for the Volumex kit.
- Capital Needs: Determine if the company will need to raise additional capital to fund the planned expansion of its sales force and R&D projects.